© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Descovy

Descoy Tablet held between tow fingers
FDA Approves Once-Daily Descovy for PrEP
Descoy Tablet and Descoy bottle
Descovy (tenofovir alafenamide + emtricitabine) 101
Chart of Approved and Experimental HIV Medications

Treatment: Best for Pregnancy

For pregnant women with HIV, dolutegravir-based regimens are apparently safest.

5,000 Walmart Pharmacies Join National “Ready, Set, PrEP” HIV Program

Safeway and other Albertsons pharmacies will also participate, allowing uninsured clients to fill PrEP prescriptions at no cost.

Coronavirus Delays PrEP Rollout in England

The country’s National Health Service was to provide the HIV prevention drug for free starting this spring.

MISTR and SISTR Help Deliver HIV Prevention PrEP to Texans’ Doorsteps

Scripts and testing don’t require visits to the doc thanks to this partnership between Texas Health Action and the telemedicine portals.
Descoy and Truvada

Yet More Gay and Bi Men May Be Good PrEP Candidates

A greater proportion of this population than previously thought could stand to benefit from pre-exposure prophylaxis.
A sample Gilead Sciences envelope

Gilead Mailers Violated HIV Customers’ Privacy, Claims Lawsuit

Envelopes were sent to people in the pharma giant’s patient assistance program for PrEP.

Adolescents on PrEP May Need More Hands-On Care

The CDC has issued a report detailing considerations for clinicians prescribing PrEP for this population.

Highlights From the First Virtual CROI

A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections

Supply of Our HIV and Hepatitis Meds Is Secure, Says Gilead

The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

For Pregnant Women With HIV, Dolutegravir-Based Regimens Are Apparently Safest

Researchers compared regimens prescribed to pregnant women in their second trimester.

HIV Prevention PrEP to Be Readily Available in England (Finally)

The country’s National Health Service will pay for the drug as part of its goal to end HIV transmission by 2030.

Adding Bictegravir to Descovy Could Simplify PEP and On-Demand PrEP in Monkeys

Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.

CROI 2020: Coronavirus Won’t (Entirely) Stop Conference

Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.

PrEP Use Tied to Some Drug Resistance in Those Who Contract HIV

In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.

Even With New, Bone-Friendly HIV Regimens, More Bone Research Is Needed

This is especially the case for people globally who don’t have access to such newer regimens.

Gilead Loses Latest Battle Over PrEP Patents, but the Fight Goes On

Who owns the rights to PrEP? The U.S. government or the pharma giant?
Advertisement
Treatment News
Blog: Undetectable = Untransmittable